Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

HeartSciences (HSCS) Equity Average (2021 - 2026)

HeartSciences' Equity Average history spans 6 years, with the latest figure at $3.4 million for Q1 2026.

  • For Q1 2026, Equity Average rose 17.77% year-over-year to $3.4 million; the TTM value through Jan 2026 reached $3.4 million, up 17.77%, while the annual FY2025 figure was $3.8 million, 0.34% changed from the prior year.
  • Equity Average reached $3.4 million in Q1 2026 per HSCS's latest filing, down from $3.7 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $8.0 million in Q2 2024 to a low of -$5.1 million in Q2 2022.
  • Average Equity Average over 5 years is $1.6 million, with a median of $1.7 million recorded in 2025.
  • Peak YoY movement for Equity Average: plummeted 154.65% in 2023, then skyrocketed 58411.6% in 2024.
  • A 5-year view of Equity Average shows it stood at $2.0 million in 2022, then plummeted by 154.65% to -$1.1 million in 2023, then skyrocketed by 558.69% to $5.0 million in 2024, then fell by 26.4% to $3.7 million in 2025, then dropped by 6.68% to $3.4 million in 2026.
  • Per Business Quant, the three most recent readings for HSCS's Equity Average are $3.4 million (Q1 2026), $3.7 million (Q4 2025), and $1.7 million (Q3 2025).